Worldwide Clinical Trials and Science 37® Partner to Advance Agile Clinical Trials™ and Accelerate Study Timelines

NEXT STORY
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers
PREV STORY
Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting

Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with ...

author_avatar
NASDAQ Market News

Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis

Zessly® (infliximab) matched the reference medicine in terms of safety and efficacy at 54 ...

author_avatar
NASDAQ Market News

Innovation Pharmaceuticals Establishing European Subsidiary; CEO Increases Equity Stake in IPIX

BEVERLY, Mass., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a ...

author_avatar
NASDAQ Market News